Skip to main content

Week In Review: Suzhou's Adagene Raises $140 Million In US IPO To Develop Oncology Drugs

Adagene, a Suzhou immunoncology biopharma, completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Adagene has a market capitalization of about $1 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.